The present disclosure provides methods of treating produce, said method comprising the step of contacting the produce with a ferrate solution. According to the present disclosure, the described methods can prolong shelf life of the produce, disinfect the produce, and/or decontaminate the produce. Advantageously, methods of the present disclosure can be used in a multitude of settings, including agriculture fields, processing facilities, and stores such as grocery stores and supermarkets to improve food supply of produce and prevent illness outbreaks.
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
A23L 5/00 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux
A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
Described herein are coating compositions and methods of treating fruits and vegetables to resemble the visual appearance of a natural wax bloom on the surface of the fruit or vegetable. The coating composition including a coating agent. The method including applying a coating composition to a surface of the fruit or vegetable, and drying the coating composition on the surface of the fruit or vegetable.
A23B 7/16 - Recouvrement à l'aide d'une couche protectrice; Compositions ou appareils à cet effet
A23L 3/00 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires
A23L 3/34 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires par traitement au moyen de produits chimiques
3.
SELECTIVE SMALL MOLECULE AGONISTS AND PARTIAL AGONISTS OF TRK RECEPTORS
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as diseases of the eye.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
US HYBRID CORPORATION (USA)
Inventeur(s)
Toliyat, Hamid A.
Praslicka, Bryton
Zamarron, Daniel
Gardner, Matthew C.
Johnson, Matthew C.
Goodarzi, Abas
Bauk, Enzo
Nguyen, Alex
Hasanpour, Shima
Duan, Godwin Yuan
Khan, Salek Ahmed
Abrégé
Aspects of the disclosure relate to a cycloidal magnetic gear. The cycloidal magnetic gear includes an outer rotor. A plurality of magnetic pole pairs is disposed on an inner circumference of the outer rotor. A first, second, and third inner rotor is disposed within the outer rotor. The first, second, and third inner rotors includes a magnetic pole pairs disposed on an outer circumference thereof. The first inner rotor and the third inner rotor have a thickness of approximately half the thickness of the second inner rotor. The first inner rotor, the second inner rotor, and the third inner rotor balance moments acting on a drive shaft.
F16H 1/28 - Transmissions à engrenages pour transmettre un mouvement rotatif avec engrenages à mouvement orbital
F16H 1/34 - Transmissions à engrenages pour transmettre un mouvement rotatif avec engrenages à mouvement orbital comportant des engrenages ayant essentiellement des éléments engrenants autres que des dentures à développante ou cycloïdales
A method of removing pollutants from flue gas includes cooling the flue gas to remove condensed water. The flue gas is then compressed and dehydrated. The dehydrated flue gas is chilled to separate pollutants.
B01D 53/04 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01D 53/28 - Emploi de substances spécifiées comme agents desséchants
F25J 3/02 - Procédés ou appareils pour séparer les constituants des mélanges gazeux impliquant l'emploi d'une liquéfaction ou d'une solidification par rectification, c. à d. par échange continuel de chaleur et de matière entre un courant de vapeur et un courant de liquide
The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/4468 - Pipéridines non condensées, p.ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p.ex. clébopride, fentanyl
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating polypeptides. The methods can involve administering serum amyloid P-component to a patient suffering from CALD or cytokine storm.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
8.
COMPOSITIONS AND METHODS FOR INHIBITION OF SARS-COV-2 VIRAL INFECTIONS
The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) main protease (MPro) in a patient. The disclosure also provides other methods as well as pharmaceutical formulations for use in treating COVID-19 patients.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
9.
MICROFLUIDIC PRESSURE IN PAPER (UPIP) FOR ULTRA LOW-COST PRECISION MICRO TOTAL ANALYSIS SYSTEMS
A method for producing a microfluidic device includes creating a paper channel using a cutting device (e.g., a laser cutter, scissors, dies, blade, or the like), placing the paper channel between two sheets of PDMS, treating the PDMS sheets with a corona plasma to adhere the PDMS sheets together, and using heat to laminate the microfluidic device.
G02B 1/04 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques faits de substances organiques, p.ex. plastiques
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
H01B 1/20 - Matériau conducteur dispersé dans un matériau organique non conducteur
A process for isolating astatine includes (a) contacting a composition comprising astatine and bismuth with nitric acid to form a first solution comprising astatine, bismuth, and nitric acid; (b) contacting a resin with the first solution so that astatine partitions out of the first solution and into the resin; and (c) eluting astatine from the resin. A composition comprising astatine may be of the formula AtO+X-, wherein X- is a counterion.
B01D 15/12 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/42 - Adsorption sélective, p.ex. chromatographie caractérisée par le mode de développement, p.ex. par déplacement ou par élution
C22B 61/00 - Obtention des métaux non prévus ailleurs dans la présente sous-classe
11.
FOAMING SYSTEM FOR EFFICIENT PLASMA PROCESSING OF HEAVY HYDROCARBON
An apparatus for converting heavy hydrocarbons to light hydrocarbons includes an inlet capable of supplying a pre-foaming mixture comprising a hydrocarbon to be processed and a processing gas, wherein the processing gas is dissolved in the hydrocarbon to be processed; a foam generator configured to receive the pre-foaming mixture at a first pressure, compress the pre-foaming mixture to a second pressure that is higher than the first pressure by routing it through a nozzle; and generate a foam by allowing the pre-foaming mixture at the second pressure to expand in a chamber at a third pressure that is lower than the first or second pressures; a plasma reactor, wherein the plasma reactor is capable of receiving the foam and comprises at least one pair of spark gap electrodes capable of subjecting the foam to a plasma discharge to yield a processed mixture; and an outlet capable of receiving the processed mixture.
Methods of treating endometriosis through modulation of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) activity including administration of an NR4A1 ligand to an individual in need thereof are described. In an embodiment, the compounds include methylene substituted diindolylmethanes.
A method of waste treatment includes treating partially-dewatered matrix with a first electron-beam radiation dose. The treated partially-dewatered matrix is transferred to a digester where the treated partially-dewatered matrix is subjected to anaerobic digestion. Biogas is recovered from the treated partially-dewatered matrix during the anaerobic digestion. The treated partially-dewatered matrix is dried and subjected to a second electron-beam radiation dose.
A23J 1/00 - Préparation des compositions à base de protéines pour l'alimentation; Ouverture des œufs par grandes quantités et séparation du jaune du blanc
A system for monitoring fluid properties in real-time, where the system includes a flow loop having a fluid inlet and a fluid outlet. In some embodiments, the flow loop includes a plurality of pipe sections forming the flow loop, where each of pipe section of the plurality of pipe sections are in fluid communication with each other and sensors fluidly coupled to each of the pipe sections perpendicular to fluid flow within each of the pipe sections. In some embodiments, each of the pipe sections has varying inner diameters. In some embodiments, the sensors measure fluid at different velocities corresponding to the varying inner diameters of each of the pipe sections.
G01N 11/00 - Recherche des propriétés d'écoulement des matériaux, p.ex. la viscosité, la plasticité; Analyse des matériaux en déterminant les propriétés d'écoulement
G01N 11/04 - Recherche des propriétés d'écoulement des matériaux, p.ex. la viscosité, la plasticité; Analyse des matériaux en déterminant les propriétés d'écoulement en mesurant l'écoulement du matériau à travers un passage étroit, p.ex. un tube, une ouverture
G01N 11/14 - Recherche des propriétés d'écoulement des matériaux, p.ex. la viscosité, la plasticité; Analyse des matériaux en déterminant les propriétés d'écoulement en déplaçant un corps à l'intérieur du matériau en utilisant des corps en rotation, p.ex. moulinet
G01N 11/16 - Recherche des propriétés d'écoulement des matériaux, p.ex. la viscosité, la plasticité; Analyse des matériaux en déterminant les propriétés d'écoulement en déplaçant un corps à l'intérieur du matériau en mesurant l'effet d'amortissement sur un corps oscillant
G01N 15/05 - Recherche de la sédimentation des suspensions de particules dans du sang
15.
XENOGEN-FREE MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF USE
The data presented herein relates to therapeutic compositions of mesenchymal stem cells (MSCs). In particular, pharmaceutically acceptable MSC compostions are xenogen-free and do not have immunological adverse effects. Mesenchymal stem cells expanded in a cell culture media comprising bone marrow supernatant produce xenogen-free mesenchymal stem cells. Such xenogen-free MSC compositions improve therapy for medical conditions including, but not limited to, osteoarthritis, cardiovascular disorders and/or diabetes.
In an embodiment, the present disclosure pertains to a method of treating a disease by induction of activity in cells. Generally, the method includes administering a bis-indole- derived compound to a subject in need thereof. In some embodiments, the method further includes binding, by the bis-indole-derived compound, to at least one of nuclear receptor 4A1 (NR4A1) and nuclear receptor 4A2 (NR4A2). In another embodiment, the present disclosure pertains to a compound for treating a disease by induction of activity in cells. Generally, the compound includes a bis-indole-derived compound. In some embodiments, the bis-indole-derived compound binds to at least one of NR4A1 and NR4A2.
C07D 487/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient deux hétérocycles
A passive infrared (PIR) sensor system, includes a PIR sensor configured to produce an output signal in response to receiving infrared (IR) radiation, an electronic shutter positionable in a field of view (FOV) of the PIR sensor, wherein the electronic shutter includes a liquid crystal (LC) material, wherein the electronic shutter includes a first state providing a first transmissivity of IR radiation through the electronic shutter and a second state providing a second transmissivity of IR radiation through the electronic shutter that is less than the first transmissivity, and a shutter actuator configured to apply an actuation signal to the electronic shutter to actuate the electronic shutter between the first state and the second state.
The present disclosure relates to methods of preventing or inhibiting fibrosis using small molecule sialidase inhibitors. The present disclosure also relates to methods treating obesity, liver inflammation, steatosis, and cancer. These methods can involve administering the compounds to a patent at risk of developing fibrosis inflammation, obesity, steatosis, or cancer, in a manner that inhibits NEU3.
Systems and methods for drilling a borehole are disclosed. In an embodiment, the system includes a drill bit and a plasma inducing apparatus coupled to the drill bit. The plasma inducing apparatus is configured to generate plasma.
A cable anchor deflector bracket (400, 500, 600) includes a first portion (404) and a second portion (402). The first portion is coupled to a guardrail (12) at a location adjacent to a cable anchor bracket (310), which is an attachment point where a cable (305) couples to the guardrail. The second portion slopes outwardly away from the guardrail and is proximate to an end of the cable anchor bracket and the end of the cable anchor assembly.
E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation
21.
COMPOSITIONS FOR THE TREATMENT OF COPPER DEFICIENCY AND METHODS OF USE
In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.
Provided is an approach for scaling up a multiphase plasma chemical reactor that uses gas bubble discharge in liquids. One example involves single spark gap discharge scale up systems and processes with suitable characteristic parameters. Scaling parameters are based on the size change of one spark gap. Another example involves scale-up systems and processes that can be applied to multiple spark gaps with multiple discharge modules and its dimension information. Numbers of modules and resulting device sizes could be based on required production rate and specific energy input. Applications allow for scaling up of any plasma chemical system or process with similar mechanisms and reactors, such oil treatment reactors.
C10G 15/12 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques avec des gaz surchauffés dans des arcs électriques, p.ex. avec un plasma
23.
SUBMERGED METHANE AND HYDROGEN MIXTURE DISCHARGE IN LIQUID HYDROCARBONS
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
C10G 47/22 - Craquage non catalytique, en présence d'hydrogène
A process for continuously upgrading heavy oil to produce light hydrocarbon gases which are recycled in the process as a carrier gas used in spark-discharge hydrocarbon cracking within the process. The process also produces light hydrocarbon liquids which are used to upgrade the heavy oil. An apparatus for continuously upgrading heavy oil to produce light hydrocarbon gases which are recycled in the as a carrier gas used in spark-discharge hydrocarbon cracking within the apparatus. The apparatus also produces light hydrocarbon liquids which are used to upgrade the heavy oil.
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
C10G 15/12 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques avec des gaz surchauffés dans des arcs électriques, p.ex. avec un plasma
25.
EFFICIENT CIRCUIT IN PULSED ELECTRICAL DISCHARGE PROCESSING
Disclosed are example efficient circuits that produce spark discharges for hydrocarbon conversion (or treatment of other mixtures) using a high-voltage rectified DC supply to discharge a capacitor (either internal or external) across a two-electrode gap, optimized to minimize waste energy by operating in a constant current, approximately-constant current, or constant power mode. The circuits may operate off of a standard electrical supply line (e.g. 120VAC or 240V AC, 60Hz, single-phase or multi-phase). The disclosed approach is scalable to any number of discharge gaps while maintaining similar pulse characteristics and electrical efficiency.
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
26.
GRACILIN A AND CONGENERS AS IMMUNOSUPPRESSIVE AND NEUROPROTECTIVE AGENTS
C07D 307/89 - Benzo [c] furannes; Benzo [c] furannes hydrogénés avec deux atomes d'oxygène liés directement en positions 1 et 3
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07C 69/16 - Esters d'acide acétique de composés dihydroxylés
C07D 307/88 - Benzo [c] furannes; Benzo [c] furannes hydrogénés avec un atome d'oxygène lié directement en position 1 ou 3
27.
PROCESSES FOR CONVERTING BIOMASS INTO HIGH-VALUE PRODUCTS
A biomass processing system is disclosed whereby a counter flow path is provided for recovering yielded product from at least two fermentation stages. In certain configurations, the counter flow path is associated with respective extraction stages that correspond to each respective fermentation stages. To enhance product recovery, certain configurations also disclose mechanical grinding of biomass between fermentation stage to enhance a surface area for further subsequent processing of the biomass. To yet further enhance the system, certain configurations discloses a cell recovery sub-system that agitates processed biomass to separate cells from undigested residues. The recovered cells may be recycled to fermentation stages in the system.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/107 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens pour recueillir les gaz de fermentation, p.ex. le méthane
C12M 1/113 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens pour recueillir les gaz de fermentation, p.ex. le méthane avec transport du substrat pendant la fermentation
C12P 7/40 - Préparation de composés organiques contenant de l'oxygène contenant un groupe carboxyle
Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5'-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
29.
MESENCHYMAL STEM/STROMAL CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF IN AUTOIMMUNE DISEASES
Pharmaceutically acceptable preparations of extracellular vesicles derived from activated MSCs are provided. These preparations are essentially free of MSCs, and demonstrate anti- inflammatory inhibiting pharmacological activity in vivo. Methods for using the preparations to prevent the onset of autoimmune diseases are presented. The MSC derived extracellular vesicles are provided in pharmaceutically acceptable preparations with a carrier, such as saline, and may be used to inhibit activation of antigen presenting cells. These preparations may also be used to suppress the development of T helper 1 (Th1) and Th17 cells. The disclosed activated MSC - derived extracellular vesicle preparations are essentially free of MSCs and other cells. Methods and preparations for treating and/or inhibiting the inflammatory response attendant organ transplant, diseases including human uveitis, type 1 diabetes, scleroderma, rheumatoid arthritis, lupus, Sjorgren's syndrome, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, multiple sclerosis, anti-glomerular basement membrane disease, and pemphigoid diseases, are also provided.
NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
Systems and methods for detecting defects in pipelines are disclosed. In one embodiment, a method for detecting defects in pipelines includes: generating an electrical signal in a first pipeline by a signal generator electrically connected with the first pipeline and a second pipeline. A reflected signal is acquired by data acquisition equipment electrically connected with the first pipeline and the second pipeline. The reflected signal at least partially reflects from a defect in the first pipeline or the second pipeline. The method also includes analyzing the reflected signal to determine at least one of a location of the defect and a severity of the defect. In some embodiments, the first pipeline and a second pipeline are connected with a shunt cable.
G01N 27/82 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables magnétiques pour rechercher la présence des criques
G01M 3/14 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite par observation d'enveloppes ou de revêtements élastiques, p.ex. eau savonneuse pour soupapes
G01M 3/16 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite en utilisant des moyens de détection électrique
G01M 3/18 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite en utilisant des moyens de détection électrique pour soupapes
G01N 29/11 - Analyse de solides en mesurant l'atténuation des ondes acoustiques
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Sharma, Virender K.
Jinadatha, Chetan
Abrégé
Methods for disinfecting a surface are provided which include contacting a surface with a solution comprising Fe(VI)O4 2-, thereby disinfecting the surfaces. In some cases, the surface to be contacted with the solution is in a space suitable for human occupancy and the surface is arranged in the ambient of the space. In addition, solutions comprising Fe(VI)O4 2- are provided. The solutions may additionally include a hypohalite salt and a surfactant.
A01N 25/02 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des liquides comme supports, diluants ou solvants
A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
A01P 1/00 - Désinfectants; Composés antimicrobiens ou leurs mélanges
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des substances chimiques des substances liquides
33.
MIXED ALUMINUM (III) AND IRON (II) SALT SOLUTION FOR ENHANCING THE HYBRID ZERO-VALENT IRON MEDIA SYSTEM REACTIVITY FOR TREATING METAL-CONTAMINATED WASTEWATER
Methods for reducing the concentration of one or more contaminants in water using zero-valent iron media. In the method, a mixed aluminum (III) and iron (II) salt solution is added to water containing one or more contaminants that is in contact with a zero-valent iron media that comprises (a) a reactive solid comprising zero-valent iron and one or more iron oxide minerals in contact therewith and (b) magnetite to provide an aqueous reaction medium. The aqueous reaction medium is contacted with the zero-valent iron media for a period of time sufficient to reduce the concentration of one or more of the contaminants.
C02F 1/70 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par réduction
B01D 15/00 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solides; Appareillages pour ces procédés
B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe
C02F 1/00 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout
34.
ENDOLYSOSOMAL TARGETING CONJUGATES FOR IMPROVED DELIVERY OF CARGO MOLECULES TO THE ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS
Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
Synthetic compositions comprising a plant element and at least one fungal endophyte are described. The fungal endophyte is capable of improving plant tolerance to biotic stress as compared to a reference plant element not further comprising the endophyte. Examples of biotic stress include the biotic stress caused by a nematode, an aphid, a fleahopper, a lygus bug, a stink bug, a soy looper, a cabbage looper, or a fungus.
The present disclosure includes a fusion protein, called a "Seldeg", including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
PULMOTECT, INC. (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Dickey, Burton F.
Tuvim, Michael J.
Evans, Scott E.
Hook, Magnus
Huston, David P.
Martinez-Moczygemba, Margarita
Scott, Brenton
Abrégé
Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist / PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
A transition barrier for transitioning from a permanent median barrier to a temporary median barrier, the transition barrier having: a) a first end; the first end being connectable to the permanent median barrier by a permanent median barrier connector; b) a second end; the second end being connectable to the temporary median barrier by a temporary median barrier connector; c) a transition section defining a transition wall of a predetermined length between the first end and the second end; the transition wall having a top, bottom, front and a back; d) at least one barrier brace proximate the transition wall, for supporting said transition wall; and e) at least one spacer, proximate the back of the transition wall for contact with a surface of the permanent concrete barrier.
E01F 15/02 - Barrières continues s'étendant le long des routes ou entre les voies de circulation
E01F 15/04 - Barrières continues s'étendant le long des routes ou entre les voies de circulation constituées essentiellement de poutres longitudinales ou de bandes rigides
E01F 15/08 - Barrières continues s'étendant le long des routes ou entre les voies de circulation constituées essentiellement par des murs ou des éléments analogues à des murs
E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation
39.
YEAST VACCINE VECTOR INCLUDING IMMUNOSTIMULATORY AND ANTIGENIC POLYPEPTIDES AND METHODS OF USING THE SAME
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Hargis, Billy
Calhoun, Leona Nicole
Berghman, Luc
Bielke, Lisa
Faulkner, Olivia B.
Abrégé
Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.
Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.
Numerous plant microbes, including the vascular-limited Candidatus spp. causal agents of citrus greening and potato zebra chip diseases are non-culturable. The present disclosure relates, according to some embodiments, to compositions, methods and systems for culturing such organisms. For example, the present disclosure relates to methods for culturing, propagating, and characterizing fastidious vascular-colonizing microbes using a hairy root system (e.g., in vitro, in planta). The present disclosure relates, in some embodiments, to methods for cultivating a fastidious plant microbe including: contacting a plant (e.g., a tomato plant, a potato plant, a citrus plant) colonized by a fastidious plant microbe (e.g., Xylella fastidiosa, Candidatus Liberibacter spp.) with a suspension of R. rhizogenes under conditions that permit induction of hairy roots colonized with the fastidious plant microbe, and propagating the colonized microbial hairy roots.
C07K 14/415 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de végétaux
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
Methods and systems for reducing the concentration of selenocyanate in water. In the methods and systems, water containing selenocyanate is treated an oxidant to provide oxidant-treated water, which is then contacted with a zero-valent iron treatment system comprising (a) a reactive solid comprising zero-valent iron and one or more iron oxide minerals in contact therewith and (b) ferrous iron.
C02F 1/72 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation
B01J 8/02 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solides; Appareillage pour de tels procédés avec des particules immobiles, p.ex. dans des lits fixes
B01J 8/24 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solides; Appareillage pour de tels procédés les particules étant fluidisées selon la technique du "lit fluidisé"
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
C02F 1/58 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par élimination de composés spécifiés dissous
C02F 1/70 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par réduction
43.
ALPHA-AMINO PATEAMINE A DERIVATIVES AND METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are a-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.
A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.à d. composés contenant un système cyclique de formule , p.ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p.ex. ticarcilline, azlocilline, oxacilline
A single anchor terminal is provided for a roadside wire rope barrier. The single anchor terminal includes a release post, a brace, and an anchor base. The brace supports the release post in an upright position and extends from the release post to the anchor base. The brace has a first portion attached to the release post and a second portion coupled to the first portion with a release component. The anchor base includes a main post that supports the release post and a brace anchor that is coupled to the main post.
E01F 15/06 - Barrières continues s'étendant le long des routes ou entre les voies de circulation constituées essentiellement de câbles, de filets ou analogues
E01F 11/00 - Bourrelets ou autres dispositifs sensibles encastrés dans les pavés ou autres revêtements routiers
A single anchor terminal is provided for a roadside wire rope barrier. The single anchor terminal includes a release post, a brace, and an anchor base. The brace supports the release post in an upright position and extends from the release post to the anchor base. The brace has a first portion attached to the release post and a second portion coupled to the first portion with a release component. The anchor base includes a main post that supports the release post and a brace anchor that is coupled to the main post.
E01F 15/06 - Barrières continues s'étendant le long des routes ou entre les voies de circulation constituées essentiellement de câbles, de filets ou analogues
E01F 11/00 - Bourrelets ou autres dispositifs sensibles encastrés dans les pavés ou autres revêtements routiers
46.
FUNGAL ENDOPHYTES FOR IMPROVED CROP YIELDS AND PROTECTION FROM PESTS
The invention provides a synthetic combination of a crop and at least one fungal endophyte, wherein the crop is a host plant of the endophyte. Provided are also methods and compositions for producing such synthetic combinations. The endophyte reproduces and enhances the agronomic characteristics of the crop. Methods for inoculating the host plant with the endophyte, for propagating the host-endophyte combination, and for detecting the presence of the endophyte and of its metabolites within a host plant are also described.
A01N 63/30 - Champignons microscopiques; Substances produites par des champignons microscopiques ou obtenues à partir de ceux-ci
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
The invention provides a synthetic combination of a crop and at least one fungal endophyte, wherein the crop is a host plant of the endophyte. Provided are also methods and compositions for producing such synthetic combinations. The endophyte reproduces and enhances the agronomic characteristics of the crop. Methods for inoculating the host plant with the endophyte, for propagating the host-endophyte combination, and for detecting the presence of the endophyte and of its metabolites within a host plant are also described.
The invention provides a synthetic combination of a crop and at least one fungal endophyte, wherein the crop is a host plant of the endophyte. Provided are also methods and compositions for producing such synthetic combinations. The endophyte reproduces and enhances the agronomic characteristics of the crop. Methods for inoculating the host plant with the endophyte, for propagating the host-endophyte combination, and for detecting the presence of the endophyte and of its metabolites within a host plant are also described.
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
A01H 17/00 - Combinaisons de symbiotes ou de parasites comprenant une ou plusieurs variétés nouvelles, p.ex. mycorrhizes
A01N 3/00 - Conservation de végétaux ou de parties de ceux-ci, p.ex. par inhibition de l'évaporation, avec amélioration de l'aspect des feuilles; Mastic à greffer
The present disclosure provides methods and compositions related to the cytosolic delivery of proteins and cell-impermeable small molecules into live cells using an endosomolytic dimer of cell-penetrating peptide TAT.
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
50.
COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO ENTERIC PATHOGENS
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Bielke, Lisa
Layton, Sherryll
Hargis, Billy
Pumford, Neil R.
Faulkner, Olivia B.
Berghman, Luc
Abi-Ghanem, Daad
Abrégé
Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD 154 polypeptide or an HMGB1 polypeptide.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
51.
COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Barta, John R.
Berghman, Luc
Bielke, Lisa
Hargis, Billy
Shivaramaiah, Srichaitanya
Faulkner, Olivia B.
Abrégé
Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.
C07K 14/44 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de protozoaires
C12N 15/30 - Gènes codant pour des protéines protozoaires, p.ex. Plasmodium, Trypanosoma, Eiméria
C12N 15/57 - Hydrolases (3) agissant sur les liaisons peptidiques (3.4)
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Methods of manufacturing biocompatible, corrosion resistant, self-adaptive, shape-memory titanium-based alloys by using specific ranges of elements in the alloy. Subsequent to melting, the alloy may undergo heat treating, thermo-mechanically processing, and training. Subsequent to training, the alloy has an ultra-low elastic modulus and exhibits self-adaptive, superelastic behavior.
The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
Compositions and/or structures of degradable shape memory polymers (SMPs) ranging in form from neat/unfoamed to ultra low density materials of down to 0.005 g/cc density. These materials show controllable degradation rate, actuation temperature and breadth of transitions along with high modulus and excellent shape memory behavior. A method of making extremely low density foams (up to 0.005 g/cc) via use of combined chemical and physical blowing agents, where the physical blowing agents may be a single compound or mixtures of two or more compounds, and other related methods, including of using multiple co-blowing agents of successively higher boiling points in order to achieve a large range of densities for a fixed net chemical composition. Methods of optimization of the physical properties of the foams such as porosity, cell size and distribution, cell openness etc. of these materials, to further expand their uses and improve their performance.
C08G 63/06 - Polyesters dérivés soit d'acides hydroxycarboxyliques, soit d'acides polycarboxyliques et de composés polyhydroxylés dérivés des acides hydroxycarboxyliques
C08G 18/10 - Procédés mettant en œuvre un prépolymère impliquant la réaction d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs, dans une première étape réactionnelle
C08G 69/26 - Polyamides dérivés, soit des acides amino-carboxyliques, soit de polyamines et d'acides polycarboxyliques dérivés de polyamines et d'acides polycarboxyliques
The invention provides recombinant Streptococcus mutans strains that can be used to improve oral health. An embodiment of the invention provides a method of reducing the incidence or severity of dental caries in a dental caries-susceptible host comprising administering orally to the host an isolated recombinant S. mutans strain of the invention in an amount effective for replacement of dental caries-causing S. mutans host strains in the oral cavity of the host. The isolated recombinant S. mutans strain 10 can be contained in a mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, or beverage.
A61P 1/02 - Préparations stomatologiques, p.ex. médicaments pour le traitement des caries, des aphtes, des périodontites
C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques
C12N 9/04 - Oxydoréductases (1.), p.ex. luciférase agissant sur des groupes CHOH comme donneurs, p.ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
According to one embodiment, a cargo inspection method includes transporting a first guideway vehicle over a guideway from a first inspection station to a second inspection station. A first non- intrusive scanning mechanism associated with the first inspection station is used to acquire a first set of data associated with cargo stored in the first guideway vehicle. The first set of data acquired by the first non-intrusive scanning mechanism associated with the first inspection station is analyzed to determine the identity of the cargo stored on the first guideway vehicle. The first set of data acquired by the first non-intrusive scanning mechanism is compared with a first manifest that describes the cargo that is declared to be stored on the first guideway vehicle. It is determined that the first guideway vehicle contains contraband cargo if the identity of the cargo does not match the first manifest.
57.
PERLECAN DOMAIN V PROTECTS, REPAIRS AND RESTORES ISCHEMIC BRAIN STROKE INJURY AND MOTOR FUNCTION
The disclosed invention relates to the use of perlecan domain V (DV) for the treatment of stroke, traumatic brain injury (TBI) or spinal cord injuries (SCI). In certain embodiments, fusion proteins of DV can be used for the treatment of stroke, TBI or SCI. DV is also referred to as endorepellin in the art. This application also provides compositions and combination therapies for the treatment of stroke, TCI and/or SCI. Another aspect of the invention provides methods of restoring motor function in subjects having neurological damage arising from a stroke, TBI or SCI.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
58.
ETS2 AND MESP1 GENERATE CARDIAC PROGENITORS FROM FIBROBLASTS
A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mespl.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Berghman, Luc
Bottje, Walter
Hargis, Billy
Layton, Sherryll
Abrégé
Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB 1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 39/145 - Orthomyxoviridae, p.ex. virus de l'influenza
The present inventors have discovered a novel composition, method of making the composition, system, process for treating a fluid containing a contaminant. The fluid may be aqueous. The contaminated fluid may be in the form of a suspension. The treatment reduces the concentration of the contaminant. The reduction in concentration of a contaminant may be sufficient so as to effect remediation of the fluid with respect to the contaminant. The treatment may reduce the concentration of a plurality of contaminants. The present composition, system, and process are robust and flexible. The composition includes zero valent iron, an iron oxide mineral, and ferrous iron. The ferrous iron promotes maintenance of the iron oxide mineral. The iron oxide mineral promotes the activity of the zero valent iron. The process and system may involve multiple stages. A stage may be optimized for treatment with respect to a particular contaminant. The present composition, system, and process are effective for treating a fluid containing one or more of a variety of contaminants such as toxic metals, metalloids, oxyanions, and dissolved silica. It may be applied to treating various aqueous fluids, such as groundwater, subsurface water, and aqueous industrial waste streams.
The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, ad-ministering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating or enhancing genera-tion of blood vessels. The present invention is drawn to compositions for enhancing angiogenesis.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
62.
GUARDRAIL SAFETY SYSTEM FOR DISSIPATING ENERGY TO DECELERATE THE IMPACTING VEHICLE
A terminal portion of a guardrail safety system includes a terminal portion of a guardrail beam that slopes from a height appropriate for redirecting an errant vehicle to a height proximate the surface of the ground at an upstream end of the terminal portion. Support posts are coupled to the terminal portion of the guardrail beam. A terminal support post installed adjacent the roadway at an upstream end of the end terminal. The terminal support post is coupled to an upstream end of the terminal portion of the guardrail beam by a coupling that maintains tension in the terminal portion of the guardrail beam. The coupling is maintained between the terminal support post and the guardrail beam during an end-on or re-directive impact by a vehicle and is released between the terminal support post and the guardrail beam during a reverse-direction impact.
E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation
63.
GUARDRAIL SAFETY SYSTEM FOR DISSIPATING ENERGY TO DECELERATE THE IMPACTING VEHICLE
Provided herein is a guardrail safety system comprising a guardrail beam comprising a W-beam having a downstream end and an upstream end. A terminal portion of the W-beam slopes from a first vertical height appropriate for redirecting an errant vehicle to a second vertical height proximate the surface of the ground. An upstream end of the W-beam comprises a vertically flattened W-beam that is coupled to a terminal support post. A plurality of support posts coupled to the guardrail beam are installed adjacent a roadway. An end treatment is releasably coupled to at least one post. The upstream end of the W-beam is vertically flattened in an assembled state and prior to impact. The end treatment is advanced longitudinally along the guardrail in a downstream direction upon impact. The advancement of the end treatment dissipates energy to decelerate the impacting vehicle and flattens the guardrail vertically.
E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation
64.
COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
UNIVERSITY OF GUELPH (Canada)
Inventeur(s)
Bottje, Walter
Hargis, Billy
Berghman, Luc
Kwon, Young, Min
Cole, Kimberly
Cox, Mandy
Layton, Sherryll
El-Ashram, Saeed
Barta, John
Tellez, Guillermo
Abrégé
Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
UNIVERSITY OF GUELPH (Canada)
Inventeur(s)
Bottje, Walter
Hargis, Billy
Berghman, Luc
Kwon, Young Min
Cole, Kimberly
Cox, Mandy
Layton, Sherryll
El-Ashram, Said
Barta, John
Tellez, Guillermo
Abrégé
Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
UNIVERSITY OF GUELPH (Canada)
Inventeur(s)
Bottje, Walter
Hargis, Billy
Berghman, Luc
Kwon, Young Min
Cole, Kimberly
Cox, Mandy
Layton, Sherryll
El-Ashram, Said
Barta, John
Tellez, Guillermo
Abrégé
Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
According to one embodiment, a transport interchange system (10) includes a roadway (20) that intersects a guideway system (14) such that the roadway is discontinuous across the guideway system. A guideway (16) vehicle is provided that transports an intermodal container (12) over the guideway system. The guideway vehicle is operable to rotate the intermodal container from a first position in which the intermodal container is parallel to the roadway to a second position in which the intermodal container is parallel to the guideway vehicle.
THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Carney, Darrell H.
Olszewska-Pazdrak, Barbara
Fossum, Theresa W.
Abrégé
Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 9/08 - Vasodilatateurs pour des indications multiples
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
The invention relates to a stabilized synthetic honey bee brood pheromone and methods of stabilizing the synthetic honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized synthetic pheromone can be used to manipulate the behaviour and improve the performance of worker honey bees, resulting in an overall increased vigour of the hive. The stabilized synthetic honey bee pheromone composition comprises two or more of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl lmolenate, methyl oleate, methyl palmitate and methyl stearate and an antioxidant.
A61K 31/23 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p.ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone
The present invention relates to novel derivatives of glycyrrhetimc acid of Formula (I), compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefit from an upregulation of PPAR.gamma. and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes and Huntmgton's disease.
C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07J 53/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par condensation avec des cycles carbocycliques ou par formation d'un cycle additionnel par une liaison directe entre deux atomes de carbone cycliques
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
The present invention provides a method for the prevention/treatment of bark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone.
A01N 43/90 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant plusieurs hétérocycles déterminants condensés entre eux ou avec un système carbocyclique commun
According to one embodiment of the invention, a freight transportation system includes a track comprising a pair of rails and a linear motor reaction plate disposed between the rails and a transport vehicle having a universal intermodal container bay configured to accommodate a plurality of containers. The transport vehicle includes one or more suspension systems each having a plurality of steel wheels engaged with the rails. The freight transportation system further includes a linear induction propulsion system coupled to the transport vehicle and operate e to work in conjunction with the linear motor reaction plate to move the transport vehicle, and a control system coupled to the linear induction propulsion system and operable to control the movement of the transport vehicle.
A rail system for a freight transportation system, comprising: a concrete substrate; a plurality of flat rail sections coupled to the concrete substrate and arranged in an end-to-end manner; wherein the junction of adjacent rail sections comprise at least one protrusion coupled to a first end of one of the rail sections and at least one recess formed in a second end of the other rail section; and wherein the protrusion is disposed within the recess in such a manner that a spacing exists between a free end of the protrusion and a bottom of the recess to allow the rail sections to expand and contract as the temperature of the rail sections change.
According to one embodiment of the invention, a method for biomedical imaging includes directing time-varying excitation light at a surface area of a light scattering material, the material comprising a fluorescent target. Time- varying emission light from the fluorescent target is detected, substantially at a two~dimensional sensor surface, in response to the time-varying excitation light stimulating the fluorescent target. The time-varying emission light is filtered to reject excitation light re-emitted from the material. A three-dimensional image of the fluorescent target is generated based on the detection substantially at the sensor surface.